NCT01649336View on ClinicalTrials.gov

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

MEK162, MEK inhibitor; oral

multiple dose, escalating

DRUG

Paclitaxel, mitotic inhibitor; intravenous

multiple dose, single schedule

Trial Locations (4)

Unknown

Pfizer Investigational Site, Scottsdale

Pfizer Investigational Site, Lafayette

Pfizer Investigational Site, New York

Pfizer Investigational Site, Oklahoma City

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01649336 - A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | Biotech Hunter | Biotech Hunter